Moderna price target raised to $45 from $36 at UBS

UBS raised the firm’s price target on Moderna (MRNA) to $45 from $36 and keeps a Neutral rating on the shares. A slew of pipeline updates are coming, and positive data could help shift the sentiment around, the analyst tells investors in a research note.